36 results on '"Principe, Maria Ilaria del"'
Search Results
2. Age, Successive Waves, Immunization, and Mortality in Elderly COVID-19 Haematological Patients: EPICOVIDEHA Findings
- Author
-
ROSSI, Giuseppe, primary, SALMANTON-GARCÍA, Jon, additional, CATTANEO, Chiara, additional, MARCHESI, Francesco, additional, DÁVILA-VALLS, Julio, additional, MARTÍN-PÉREZ, Sonia, additional, ITRI, Federico, additional, LÓPEZ-GARCÍA, Alberto, additional, GLENTHØJ, Andreas, additional, SILVA, Maria GOMES DA, additional, BESSON, Caroline, additional, MARCHETTI, Monia, additional, WEINBERGEROVÁ, Barbora, additional, JAKSIC, Ozren, additional, JIMÉNEZ, Moraima, additional, BILGIN, Yavuz M., additional, DOESUM, Jaap VAN, additional, FARINA, Francesca, additional, ŽÁK, Pavel, additional, VERGA, Luisa, additional, COLLINS, Graham P., additional, BONUOMO, Valentina, additional, PRAET, Jens VAN, additional, NUCCI, Marcio, additional, MEERS, Stef, additional, ESPIGADO, Ildefonso, additional, FRACCHIOLLA, Nicola S., additional, VALKOVIĆ, Toni, additional, POULSEN, Christian Bjørn, additional, ČOLOVIĆ, Natasha, additional, DRAGONETTI, Giulia, additional, LEDOUX, Marie-Pierre, additional, TASCINI, Carlo, additional, BUQUICCHIO, Caterina, additional, BLENNOW, Ola, additional, PASSAMONTI, Francesco, additional, MACHADO, Marina, additional, LABRADOR, Jorge, additional, DUARTE, Rafael F., additional, SCHÖNLEIN, Martin, additional, PREZIOSO, Lucia, additional, FALCES-ROMERO, Iker, additional, KULASEKARARAJ, Austin, additional, GARCIA-VIDAL, Carolina, additional, FERNÁNDEZ, Noemí, additional, ABU-ZEINAH, Ghaith, additional, ORMAZABAL-VÉLEZ, Irati, additional, ADŽIĆ-VUKIČEVIĆ, Tatjana, additional, PIUKOVICS, Klára, additional, STOMA, Igor, additional, CUCCARO, Annarosa, additional, MAGLIANO, Gabriele, additional, SZOTKOWSKI, Tomáš, additional, GONZÁLEZ-LÓPEZ, Tomás-José, additional, EL-ASHWAH, Shaimaa, additional, BERGANTIM, Rui, additional, SILI, Uluhan, additional, MAERTENS, Johan, additional, DEMIRKAN, Fatih, additional, RAMÓN, Cristina DE, additional, PETZER, Verena, additional, PRINCIPE, Maria Ilaria DEL, additional, NAVRÁTIL, Milan, additional, DARGENIO, Michelina, additional, SEVAL, Guldane Cengiz, additional, SAMARKOS, Michail, additional, RÁČIL, Zdeněk, additional, PINCZÉS, László Imre, additional, LAHMER, Tobias, additional, BUSCA, Alessandro, additional, MÉNDEZ, Gustavo-Adolfo, additional, VENA, Antonio, additional, BIERNAT, Monika M., additional, MERELLI, Maria, additional, CALBACHO, Maria, additional, BARAĆ, Aleksandra, additional, BAVASTRO, Martina, additional, LIMONGELLI, Alessandro, additional, ILHAN, Osman, additional, WOLF, Dominik, additional, ÇOLAK, Gökçe Melis, additional, GARCÍA-SANZ, Ramón, additional, EMARAH, Ziad, additional, MIŠKOVIĆ, Bojana, additional, GRÄFE, Stefanie, additional, MLADENOVIĆ, Miloš, additional, AIELLO, Tommaso Francesco, additional, NÚÑEZ-MARTÍN-BUITRAGO, Lucía, additional, NORDLANDER, Anna, additional, ARELLANO, Elena, additional, ZAMBROTTA, Giovanni Paolo Maria, additional, AMMATUNA, Emanuele, additional, CABIRTA, Alba, additional, SACCHI, Maria Vittoria, additional, RODRIGUES, Raquel NUNES, additional, HERSBY, Ditte Stampe, additional, HANAKOVA, Michaela, additional, RAHIMLI, Laman, additional, CORDOBA, Raul, additional, CORNELY, Oliver A., additional, and PAGANO, Livio, additional
- Published
- 2023
- Full Text
- View/download PDF
3. P1509: CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND PREVIOUS INFECTIONS HAD IMPACT ON INFECTIOUS COMPLICATIONS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH VENETOCLAX: A MULTICENTRE SEIFEM STUDY
- Author
-
Autore, Francesco, primary, Visentin, Andrea, additional, Deodato, Marina, additional, Vitale, Candida, additional, Galli, Eugenio, additional, Fresa, Alberto, additional, Fazzi, Rita, additional, Sanna, Alessandro, additional, Olivieri, Jacopo, additional, Scortechini, Ilaria, additional, Principe, Maria Ilaria DEL, additional, Sportoletti, Paolo, additional, Schiattone, Luana, additional, Maschio, Nilla, additional, Facchinelli, Davide, additional, Coscia, Marta, additional, Tedeschi, Alessandra, additional, Trentin, Livio, additional, Innocenti, Idanna, additional, Candoni, Anna, additional, Busca, Alessandro, additional, Pagano, Livio, additional, and Laurenti, Luca, additional
- Published
- 2023
- Full Text
- View/download PDF
4. Correspondence in reference to the previously published manuscript: Reduction of cycles of bendamustine plus rituximab therapy in the cases with good response for indolent B-cell lymphomas
- Author
-
Autore, Francesco, Fresa, Alberto, Innocenti, Idanna, Principe, Maria Ilaria Del, Maglione, Raffaele, Stefanizzi, Caterina, Pelliccia, Sabrina, Romeo, Azzurra, Cimino, Giuseppe, Papa, Elena, Padua, Laura De, Andriani, Alessandro, Mengarelli, Andrea, Tafuri, Agostino, Ditto, Concetta, Mauro, Francesca Romana, Del Poeta, Giovanni, Laurenti, Luca, Laurenti, Luca (ORCID:0000-0002-8327-1396), Autore, Francesco, Fresa, Alberto, Innocenti, Idanna, Principe, Maria Ilaria Del, Maglione, Raffaele, Stefanizzi, Caterina, Pelliccia, Sabrina, Romeo, Azzurra, Cimino, Giuseppe, Papa, Elena, Padua, Laura De, Andriani, Alessandro, Mengarelli, Andrea, Tafuri, Agostino, Ditto, Concetta, Mauro, Francesca Romana, Del Poeta, Giovanni, Laurenti, Luca, and Laurenti, Luca (ORCID:0000-0002-8327-1396)
- Abstract
Takezaki et al. analyzed the outcome of 57 patients with indolent lymphomas treated with Bendamustine plus Rituximab (BR) according to the number of cycles received, showing that patients who discontinued BR after four cycles had similar outcomes compared to patients who received five or six cycles. Considering the similarities but also the differences between indolent lymphomas and chronic lymphocytic leukemia (CLL), we enriched the results obtained with a cohort of CLL patients treated with BR starting from the experience of the Lazio region group on CLL. Out of 115 patients, 97 (84%) received 4-6 cycles of BR, while 18 (16%) received 1-3 cycles. The outcome of the group of patients who received at least 4 cycles was superior in terms of response rate (ORR 96% vs. ORR 83%, p = 0.041; CR 58% vs. CR 28%, p = 0.052 respectively) and PFS [median PFS 52.6 (40.3-64.9) versus 26.2 (19.3-33.0) months, p < 0.001]. The number of patients undergoing 4 cycles of BR (4-cycles group) and 5-6 cycles (over-4-cycles group) was 9 and 88, respectively. Compared to analysis conducted by the Japanese group in indolent lymphomas, in CLL we did not observe any difference between the outcome of the 4-cycles group and the over-4-cycles group in terms of ORR (89% vs. 97%, p = 0.268) and in survival [median PFS 40.8 (13.7-67.8) versus 52.6 (38.7-66.5) months, p = 0.117]. Moreover, we observed that patients who achieved a clinical CR showed overlapping outcomes with patients who received more than 4 cycles [CR vs. non-CR median PFS not reached vs. 11.0 months; over-4-cycles group median PFS 52.6 months (40.3-64.9); p < 0.001]. Nowadays chemoimmunotherapy with BR is reserved to fit elderly CLL patients, and there are many chemo-free treatment options available; therefore, discontinuation after 4 cycles may be permissible in patients who obtained a CR in order to limit toxicity as much as possible.
- Published
- 2023
5. Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments
- Author
-
Laurenti, Luca, Innocenti, Idanna, Autore, Francesco, Vannata, Barbara, Efremov, Dimitar G., Ciolli, Stefania, Del Poeta, Giovanni, Mauro, Francesca Romana, Cortelezzi, Agostino, Borza, Paola Anticoli, Ghio, Francesco, Mondello, Patrizia, Murru, Roberta, Gozzetti, Alessandro, Cariccio, Maria Rosa Lanza, Piccirillo, Nicola, Boncompagni, Riccardo, Cantonetti, Maria, Principe, Maria Ilaria Del, Reda, Gianluigi, Bongarzoni, Velia, Cervetti, Giulia, Pitini, Vincenzo, Foà, Robin, Sica, Simona, and D’Arena, Giovanni
- Published
- 2015
- Full Text
- View/download PDF
6. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)
- Author
-
Gilead Sciences, Pagano, Livio [0000-0001-8287-928X], Salmanton-García, Jon [0000-0002-6766-8297], Marchesi, Francesco [0000-0001-6353-2272], Busca, Alessandro [0000-0001-5361-5613], Corradini, Paolo [0000-0002-9186-1353], Hoenigl, Martin [0000-0002-1653-2824], Klimko, Nikolay [0000-0001-6095-7531], Koehler, Philipp [0000-0002-7386-7495], Pagliuca, Antonio [0000-0003-2519-0333], Passamonti, Francesco [0000-0001-8068-5289], Verga, Luisa [0000-0003-1142-8435], Víšek, Benjamin [0000-0001-8268-452X], Ilhan, Osman [0000-0003-1665-372X], Weinbergerová, Barbora [0000-0001-6460-2471], Córdoba, Raúl [0000-0002-7654-8836], Marchetti, Monia [0000-0001-7615-0572], Farina, Francesca [0000-0002-5124-6970], Cattaneo, Chiara [0000-0003-0031-3237], Cabirta, Alba [0000-0001-7198-8894], Gomes-Silva, Maria [0000-0002-6993-2450], Itri, Federico [0000-0002-3532-5281], Doesum, Jaap van [0000-0003-0214-3219], Ledoux, Marie-Pierre [0000-0002-3261-3616], Čerňan, Martin [0000-0003-2345-1229], Jakšić, Ozren [0000-0003-4026-285X], Magliano, Gabriel [0000-0002-9129-1530], Omrani, Ali S. [0000-0001-5309-6358], Fracchiolla, Nicola S. [0000-0002-8982-8079], Kulasekararaj, Austin G. [0000-0003-3180-3570], Valković, Toni [0000-0001-6083-8815], Poulsen, Christian Bjørn [0000-0001-9785-1378], Machado, Marina [0000-0002-8370-2248], Glenthøj, Andrea [0000-0003-2082-0738], Stoma, Igor [0000-0003-0483-7329], Ráčil, Zdeněk [0000-0003-3511-4596], Piukovics, Klára [0000-0003-4480-3131], Emarah, Ziad [0000-0003-0622-2598], Sili, Uluhan [0000-0002-9939-9298], Maertens, Johan [0000-0003-4257-5980], Bergantim, Rui [0000-0002-7811-9509], García-Vidal, Carolina [0000-0002-8915-0683], Prezioso, Lucia [0000-0003-1660-4960], Principe, Maria Ilaria del [0000-0002-3958-0669], Popova, Marina [0000-0001-8536-5495], Jonge, Nick de [0000-0002-9901-0887], Ormazabal-Vélez, Irati [0000-0003-1141-5546], Falces-Romero, Iker [0000-0001-5888-7706], Cuccaro, Annarosa [0000-0002-0237-1839], Meers, Stef [0000-0003-1754-2175], Buquicchio, Caterina [0000-0002-3683-5953], Antić, Darko [0000-0002-2608-1342], Al-Khabori, Murtadha [0000-0002-2937-8838], García-Sanz, Ramón [0000-0003-4120-2787], Biernat, Monika [0000-0003-3161-3398], Tisi, Maria Chiara [0000-0001-8231-6700], Sal, Ertan [0000-0003-2761-2675], Rahimli, Laman [0000-0003-2266-445X], Schönlein, Martin [0000-0002-1010-0975], Calbacho, María [0000-0001-8106-4863], Tascini, Carlo [0000-0001-9625-6024], Miranda-Castillo, Carolina [0000-0001-8763-9576], Khanna, Nina [0000-0002-2642-419X], Méndez, Gustavo-Adolfo [0000-0003-0514-7004], Petzer, Verena [0000-0002-9205-1440], Besson, Caroline [0000-0003-4364-7173], Duléry, Rémy [0000-0002-5024-1713], Lamure, Sylvain [0000-0001-5980-305X], Nucci, Marcio [0000-0003-4867-0014], Zambrotta, Giovanni [0000-0002-8612-2994], Žák, Pavel [0000-0003-4465-5343], Cengiz Seval, Guldane [0000-0001-9433-2054], Bonuomo, Valentina [0000-0001-6491-8337], Mayer, Jiří [0000-0003-0567-9887], López-García, Alberto [0000-0002-5354-5261], Sacchi, Maria Vittoria [0000-0001-8133-3357], Booth, Stephen [0000-0003-2687-0234], Ciceri, Fabio [0000-0003-0873-0123], Nunes-Rodrigues, Raquel [0000-0002-8347-4281], Ammatuna, Emanuele [0000-0001-8247-4901], Obr, Aleš [0000-0002-6758-3074], Herbrecht, Raoul [0000-0002-9381-4876], Shwaylia, Hawraa [0000-0002-4098-6092], Sciumè, Mariarita [0000-0001-7958-4966], Essame, Jenna [0000-0003-0926-5577], Batinić, Josip [0000-0001-5595-9911], Gonzaga, Yung [0000-0003-1416-2118], Regalado-Artamendi, Isabel [0000-0002-9673-9015], Karlsson, Linda Katharina [0000-0003-3317-7550], Shapetska, Maryia [0000-0002-1223-9161], El-Ashwah, Shaimaa [0000-0003-2210-1534], Çolak, Gökçe Melis [0000-0002-7662-7454], Dragonetti, Giulia [0000-0003-1775-6333], Rinaldi, Amelia [0000-0002-8211-5076], Ramón, Cristina de [0000-0002-8167-6410], Cornely, Oliver A. [0000-0001-9599-3137], Pagano, Livio, Salmanton-García, Jon, Marchesi, Francesco, Busca, Alessandro, Corradini, Paolo, Hoenigl, Martin, Klimko, Nikolay, Koehler, Philipp, Pagliuca, Antonio, Passamonti, Francesco, Verga, Luisa, Gonzaga, Yung, Regalado-Artamendi, Isabel, Karlsson, Linda Katharina, Shapetska, Maryia, Hanakova, Michaela, El-Ashwah, Shaimaa, Borbényi, Zita, Çolak, Gökçe Melis, Nordlander, Anna, Dragonetti, Giulia, Víšek, Benjamin, Maraglino, Alessio Maria Edoardo, Rinaldi, Amelia, Ramón, Cristina de, Cornely, Oliver A., Ilhan, Osman, Nadali, Gianpaolo, Weinbergerová, Barbora, Córdoba, Raúl, Marchetti, Monia, Collins, Graham P., Farina, Francesca, Cattaneo, Chiara, Cabirta, Alba, Gomes-Silva, Maria, Itri, Federico, Doesum, Jaap van, Ledoux, Marie-Pierre, Čerňan, Martin, Jakšić, Ozren, Duarte, Rafael F., Magliano, Gabriel, Omrani, Ali S., Fracchiolla, Nicola S., Kulasekararaj, Austin G., Valković, Toni, Poulsen, Christian Bjørn, Machado, Marina, Glenthøj, Andrea, Stoma, Igor, Ráčil, Zdeněk, Piukovics, Klára, Navrátil, Milan, Emarah, Ziad, Sili, Uluhan, Maertens, Johan, Blennow, Ola, Bergantim, Rui, García-Vidal, Carolina, Prezioso, Lucia, Guidetti, Anna, Principe, Maria Ilaria del, Popova, Marina, Jonge, Nick de, Ormazabal-Vélez, Irati, Fernández, Noemí, Falces-Romero, Iker, Cuccaro, Annarosa, Meers, Stef, Buquicchio, Caterina, Antić, Darko, Al-Khabori, Murtadha, García-Sanz, Ramón, Biernat, Monika, Tisi, Maria Chiara, Sal, Ertan, Rahimli, Laman, Čolović, Natasa, Schönlein, Martin, Calbacho, María, Tascini, Carlo, Miranda-Castillo, Carolina, Khanna, Nina, Méndez, Gustavo-Adolfo, Petzer, Verena, Novák, Jan, Besson, Caroline, Duléry, Rémy, Lamure, Sylvain, Nucci, Marcio, Zambrotta, Giovanni, Žák, Pavel, Cengiz Seval, Guldane, Bonuomo, Valentina, Mayer, Jiří, López-García, Alberto, Sacchi, Maria Vittoria, Booth, Stephen, Ciceri, Fabio, Oberti, Margherita, Salvini, Marco, Izuzquiza, Macarena, Nunes-Rodrigues, Raquel, Ammatuna, Emanuele, Obr, Aleš, Herbrecht, Raoul, Núñez-Martín-Buitrago, Lucía, Mancini, Valentina, Shwaylia, Hawraa, Sciumè, Mariarita, Essame, Jenna, Nygaard, Marietta, Batinić, Josip, Gilead Sciences, Pagano, Livio [0000-0001-8287-928X], Salmanton-García, Jon [0000-0002-6766-8297], Marchesi, Francesco [0000-0001-6353-2272], Busca, Alessandro [0000-0001-5361-5613], Corradini, Paolo [0000-0002-9186-1353], Hoenigl, Martin [0000-0002-1653-2824], Klimko, Nikolay [0000-0001-6095-7531], Koehler, Philipp [0000-0002-7386-7495], Pagliuca, Antonio [0000-0003-2519-0333], Passamonti, Francesco [0000-0001-8068-5289], Verga, Luisa [0000-0003-1142-8435], Víšek, Benjamin [0000-0001-8268-452X], Ilhan, Osman [0000-0003-1665-372X], Weinbergerová, Barbora [0000-0001-6460-2471], Córdoba, Raúl [0000-0002-7654-8836], Marchetti, Monia [0000-0001-7615-0572], Farina, Francesca [0000-0002-5124-6970], Cattaneo, Chiara [0000-0003-0031-3237], Cabirta, Alba [0000-0001-7198-8894], Gomes-Silva, Maria [0000-0002-6993-2450], Itri, Federico [0000-0002-3532-5281], Doesum, Jaap van [0000-0003-0214-3219], Ledoux, Marie-Pierre [0000-0002-3261-3616], Čerňan, Martin [0000-0003-2345-1229], Jakšić, Ozren [0000-0003-4026-285X], Magliano, Gabriel [0000-0002-9129-1530], Omrani, Ali S. [0000-0001-5309-6358], Fracchiolla, Nicola S. [0000-0002-8982-8079], Kulasekararaj, Austin G. [0000-0003-3180-3570], Valković, Toni [0000-0001-6083-8815], Poulsen, Christian Bjørn [0000-0001-9785-1378], Machado, Marina [0000-0002-8370-2248], Glenthøj, Andrea [0000-0003-2082-0738], Stoma, Igor [0000-0003-0483-7329], Ráčil, Zdeněk [0000-0003-3511-4596], Piukovics, Klára [0000-0003-4480-3131], Emarah, Ziad [0000-0003-0622-2598], Sili, Uluhan [0000-0002-9939-9298], Maertens, Johan [0000-0003-4257-5980], Bergantim, Rui [0000-0002-7811-9509], García-Vidal, Carolina [0000-0002-8915-0683], Prezioso, Lucia [0000-0003-1660-4960], Principe, Maria Ilaria del [0000-0002-3958-0669], Popova, Marina [0000-0001-8536-5495], Jonge, Nick de [0000-0002-9901-0887], Ormazabal-Vélez, Irati [0000-0003-1141-5546], Falces-Romero, Iker [0000-0001-5888-7706], Cuccaro, Annarosa [0000-0002-0237-1839], Meers, Stef [0000-0003-1754-2175], Buquicchio, Caterina [0000-0002-3683-5953], Antić, Darko [0000-0002-2608-1342], Al-Khabori, Murtadha [0000-0002-2937-8838], García-Sanz, Ramón [0000-0003-4120-2787], Biernat, Monika [0000-0003-3161-3398], Tisi, Maria Chiara [0000-0001-8231-6700], Sal, Ertan [0000-0003-2761-2675], Rahimli, Laman [0000-0003-2266-445X], Schönlein, Martin [0000-0002-1010-0975], Calbacho, María [0000-0001-8106-4863], Tascini, Carlo [0000-0001-9625-6024], Miranda-Castillo, Carolina [0000-0001-8763-9576], Khanna, Nina [0000-0002-2642-419X], Méndez, Gustavo-Adolfo [0000-0003-0514-7004], Petzer, Verena [0000-0002-9205-1440], Besson, Caroline [0000-0003-4364-7173], Duléry, Rémy [0000-0002-5024-1713], Lamure, Sylvain [0000-0001-5980-305X], Nucci, Marcio [0000-0003-4867-0014], Zambrotta, Giovanni [0000-0002-8612-2994], Žák, Pavel [0000-0003-4465-5343], Cengiz Seval, Guldane [0000-0001-9433-2054], Bonuomo, Valentina [0000-0001-6491-8337], Mayer, Jiří [0000-0003-0567-9887], López-García, Alberto [0000-0002-5354-5261], Sacchi, Maria Vittoria [0000-0001-8133-3357], Booth, Stephen [0000-0003-2687-0234], Ciceri, Fabio [0000-0003-0873-0123], Nunes-Rodrigues, Raquel [0000-0002-8347-4281], Ammatuna, Emanuele [0000-0001-8247-4901], Obr, Aleš [0000-0002-6758-3074], Herbrecht, Raoul [0000-0002-9381-4876], Shwaylia, Hawraa [0000-0002-4098-6092], Sciumè, Mariarita [0000-0001-7958-4966], Essame, Jenna [0000-0003-0926-5577], Batinić, Josip [0000-0001-5595-9911], Gonzaga, Yung [0000-0003-1416-2118], Regalado-Artamendi, Isabel [0000-0002-9673-9015], Karlsson, Linda Katharina [0000-0003-3317-7550], Shapetska, Maryia [0000-0002-1223-9161], El-Ashwah, Shaimaa [0000-0003-2210-1534], Çolak, Gökçe Melis [0000-0002-7662-7454], Dragonetti, Giulia [0000-0003-1775-6333], Rinaldi, Amelia [0000-0002-8211-5076], Ramón, Cristina de [0000-0002-8167-6410], Cornely, Oliver A. [0000-0001-9599-3137], Pagano, Livio, Salmanton-García, Jon, Marchesi, Francesco, Busca, Alessandro, Corradini, Paolo, Hoenigl, Martin, Klimko, Nikolay, Koehler, Philipp, Pagliuca, Antonio, Passamonti, Francesco, Verga, Luisa, Gonzaga, Yung, Regalado-Artamendi, Isabel, Karlsson, Linda Katharina, Shapetska, Maryia, Hanakova, Michaela, El-Ashwah, Shaimaa, Borbényi, Zita, Çolak, Gökçe Melis, Nordlander, Anna, Dragonetti, Giulia, Víšek, Benjamin, Maraglino, Alessio Maria Edoardo, Rinaldi, Amelia, Ramón, Cristina de, Cornely, Oliver A., Ilhan, Osman, Nadali, Gianpaolo, Weinbergerová, Barbora, Córdoba, Raúl, Marchetti, Monia, Collins, Graham P., Farina, Francesca, Cattaneo, Chiara, Cabirta, Alba, Gomes-Silva, Maria, Itri, Federico, Doesum, Jaap van, Ledoux, Marie-Pierre, Čerňan, Martin, Jakšić, Ozren, Duarte, Rafael F., Magliano, Gabriel, Omrani, Ali S., Fracchiolla, Nicola S., Kulasekararaj, Austin G., Valković, Toni, Poulsen, Christian Bjørn, Machado, Marina, Glenthøj, Andrea, Stoma, Igor, Ráčil, Zdeněk, Piukovics, Klára, Navrátil, Milan, Emarah, Ziad, Sili, Uluhan, Maertens, Johan, Blennow, Ola, Bergantim, Rui, García-Vidal, Carolina, Prezioso, Lucia, Guidetti, Anna, Principe, Maria Ilaria del, Popova, Marina, Jonge, Nick de, Ormazabal-Vélez, Irati, Fernández, Noemí, Falces-Romero, Iker, Cuccaro, Annarosa, Meers, Stef, Buquicchio, Caterina, Antić, Darko, Al-Khabori, Murtadha, García-Sanz, Ramón, Biernat, Monika, Tisi, Maria Chiara, Sal, Ertan, Rahimli, Laman, Čolović, Natasa, Schönlein, Martin, Calbacho, María, Tascini, Carlo, Miranda-Castillo, Carolina, Khanna, Nina, Méndez, Gustavo-Adolfo, Petzer, Verena, Novák, Jan, Besson, Caroline, Duléry, Rémy, Lamure, Sylvain, Nucci, Marcio, Zambrotta, Giovanni, Žák, Pavel, Cengiz Seval, Guldane, Bonuomo, Valentina, Mayer, Jiří, López-García, Alberto, Sacchi, Maria Vittoria, Booth, Stephen, Ciceri, Fabio, Oberti, Margherita, Salvini, Marco, Izuzquiza, Macarena, Nunes-Rodrigues, Raquel, Ammatuna, Emanuele, Obr, Aleš, Herbrecht, Raoul, Núñez-Martín-Buitrago, Lucía, Mancini, Valentina, Shwaylia, Hawraa, Sciumè, Mariarita, Essame, Jenna, Nygaard, Marietta, and Batinić, Josip
- Abstract
Background Patients with hematological malignancies (HM) are at high risk of mortality from SARS-CoV-2 disease 2019 (COVID-19). A better understanding of risk factors for adverse outcomes may improve clinical management in these patients. We therefore studied baseline characteristics of HM patients developing COVID-19 and analyzed predictors of mortality. Methods The survey was supported by the Scientific Working Group Infection in Hematology of the European Hematology Association (EHA). Eligible for the analysis were adult patients with HM and laboratory-confirmed COVID-19 observed between March and December 2020. Results The study sample includes 3801 cases, represented by lymphoproliferative (mainly non-Hodgkin lymphoma n = 1084, myeloma n = 684 and chronic lymphoid leukemia n = 474) and myeloproliferative malignancies (mainly acute myeloid leukemia n = 497 and myelodysplastic syndromes n = 279). Severe/critical COVID-19 was observed in 63.8% of patients (n = 2425). Overall, 2778 (73.1%) of the patients were hospitalized, 689 (18.1%) of whom were admitted to intensive care units (ICUs). Overall, 1185 patients (31.2%) died. The primary cause of death was COVID-19 in 688 patients (58.1%), HM in 173 patients (14.6%), and a combination of both COVID-19 and progressing HM in 155 patients (13.1%). Highest mortality was observed in acute myeloid leukemia (199/497, 40%) and myelodysplastic syndromes (118/279, 42.3%). The mortality rate significantly decreased between the first COVID-19 wave (March–May 2020) and the second wave (October–December 2020) (581/1427, 40.7% vs. 439/1773, 24.8%, p value < 0.0001). In the multivariable analysis, age, active malignancy, chronic cardiac disease, liver disease, renal impairment, smoking history, and ICU stay correlated with mortality. Acute myeloid leukemia was a higher mortality risk than lymphoproliferative diseases. Conclusions This survey confirms that COVID-19 patients with HM are at high risk of lethal complications. However
- Published
- 2021
7. Comparison between azacitidine and decitabine as front-line therapy in elderly treatment naïve Acute Myeloid Leukemia not eligible for intensive chemotherapy
- Author
-
Maurillo, Luca, primary, Spagnoli, Alessandra, additional, Candoni, Anna, additional, Papayannidis, Cristina, additional, Borlenghi, Erika, additional, Lazzarotto, Davide, additional, Fianchi, Luana, additional, Sciumè, Maria Rita, additional, Zannier, Maria Elena, additional, Buccisano, Francesco, additional, Principe, Maria Ilaria Del, additional, Mancini, Valentina, additional, Breccia, Massimo, additional, Fanin, Renato, additional, Todisco, Elisabetta, additional, Lunghi, Monia, additional, Palmieri, Raffaele, additional, Fracchiolla, Nicola, additional, Musto, Pellegrino, additional, Rossi, Giuseppe, additional, and Venditti, Adriano, additional
- Published
- 2022
- Full Text
- View/download PDF
8. COVID-19 infection in acute lymphoblastic leukemia over 15 months of the pandemic. A Campus ALL report
- Author
-
Chiaretti, Sabina, primary, Bonifacio, Massimiliano, additional, Agrippino, Roberta, additional, Giglio, Fabio, additional, Annunziata, Mario, additional, Curti, Antonio, additional, Principe, Maria Ilaria Del, additional, Salutari, Prassede, additional, Sciumè, Mariarita, additional, Delia, Mario, additional, Armenio, Marco, additional, Mancini, Valentina, additional, Mulè, Antonino, additional, Grimaldi, Francesco, additional, Rege-Cambrin, Giovanna, additional, Santoro, Lidia, additional, Lussana, Federico, additional, Chiusolo, Patrizia, additional, Pasciolla, Crescenza, additional, Scattolin, Anna Maria, additional, Cerrano, Marco, additional, Ciccone, Maria, additional, Defina, Marzia, additional, Forghieri, Fabio, additional, Mazzone, Carla, additional, Piccini, Matteo, additional, Ferrara, Felicetto, additional, Pizzolo, Giovanni, additional, and Foà, Robin, additional
- Published
- 2022
- Full Text
- View/download PDF
9. A shorter time to the first treatment may be predicted by the absolute number of regulatory T-cells in patients with Rai stage 0 chronic lymphocytic leukemia
- Author
-
DʼArena, Giovanni, DʼAuria, Fiorella, Simeon, Vittorio, Laurenti, Luca, Deaglio, Silvia, Mansueto, Giovanna, Principe, Maria Ilaria Del, Statuto, Teodora, Pietrantuono, Giuseppe, Guariglia, Roberto, Innocenti, Idanna, Martorelli, Maria Carmen, Villani, Oreste, De Feo, Vincenzo, Poeta, Giovanni Del, and Musto, Pellegrino
- Published
- 2012
- Full Text
- View/download PDF
10. Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia
- Author
-
Poeta, Giovanni Del, Principe, Maria Ilaria Del, Buccisano, Francesco, Maurillo, Luca, Capelli, Giovanni, Luciano, Fabrizio, Perrotti, Alessio Pio, Degan, Massimo, Venditti, Adriano, Fabritiis, Paolo de, Gattei, Valter, and Amadori, Sergio
- Subjects
Lymphocytic leukemia -- Drug therapy ,Lymphocytic leukemia -- Patient outcomes ,Lymphocytic leukemia -- Research ,Immunotherapy -- Patient outcomes ,Immunotherapy -- Research ,Health - Published
- 2008
11. Isavuconazole in Hematological Patients: Results of a Real-Life Multicentre Observational Seifem Study
- Author
-
Cattaneo, Chiara, primary, Busca, Alessandro, additional, Gramegna, Doriana, additional, Farina, Francesca, additional, Candoni, Anna, additional, Piedimonte, Monica, additional, Fracchiolla, Nicola, additional, Pagani, Chiara, additional, Principe, Maria Ilaria Del, additional, Tisi, Maria Chiara, additional, Offidani, Massimo, additional, Fanci, Rosa, additional, Ballanti, Stelvio, additional, Spolzino, Angelica, additional, Criscuolo, Marianna, additional, Marchesi, Francesco, additional, Nadali, Gianpaolo, additional, Delia, Mario, additional, Picardi, Marco, additional, Sciumé, Margherita, additional, Mancini, Valentina, additional, Olivieri, Attilio, additional, Tumbarello, Mario, additional, Rossi, Giuseppe, additional, and Pagano, Livio, additional
- Published
- 2019
- Full Text
- View/download PDF
12. Isavuconazole in Hematological Patients: Results of a Real-Life Multicentre Observational Seifem Study
- Author
-
Cattaneo, Chiara, Busca, Alessandro, Gramegna, Doriana, Farina, Francesca, Candoni, Anna, Piedimonte, Monica, Fracchiolla, Nicola, Pagani, Chiara, Principe, Maria Ilaria Del, Tisi, Maria Chiara, Offidani, Massimo, Fanci, Rosa, Ballanti, Stelvio, Spolzino, Angelica, Criscuolo, Marianna, Marchesi, Francesco, Nadali, Gianpaolo, Delia, Mario, Picardi, Marco, Sciumé, Margherita, Mancini, Valentina, Olivieri, Attilio, Tumbarello, Mario, Rossi, Giuseppe, Pagano, Livio, Tumbarello, Mario (ORCID:0000-0002-9519-8552), Pagano, Livio (ORCID:0000-0001-8287-928X), Cattaneo, Chiara, Busca, Alessandro, Gramegna, Doriana, Farina, Francesca, Candoni, Anna, Piedimonte, Monica, Fracchiolla, Nicola, Pagani, Chiara, Principe, Maria Ilaria Del, Tisi, Maria Chiara, Offidani, Massimo, Fanci, Rosa, Ballanti, Stelvio, Spolzino, Angelica, Criscuolo, Marianna, Marchesi, Francesco, Nadali, Gianpaolo, Delia, Mario, Picardi, Marco, Sciumé, Margherita, Mancini, Valentina, Olivieri, Attilio, Tumbarello, Mario, Rossi, Giuseppe, Pagano, Livio, Tumbarello, Mario (ORCID:0000-0002-9519-8552), and Pagano, Livio (ORCID:0000-0001-8287-928X)
- Abstract
Invasive fungal diseases (IFDs) remain a major clinical issue in patients with hematological malignancies (HMs). To confirm the efficacy and safety of the new azole isavuconazole (ISV) in a clinical care setting, we planned a multicenter retrospective study; we collected data on all possible/probable/proven IFDs in patients with HMs treated with ISV in 17 centers. Between July 2016 and November 2018, 128 patients were enrolled, and 122 were fully evaluable. ISV was employed as the 1st line therapy in 43 (35%) patients and as a subsequent therapy in 79 (65%) patients. The response rate was 82/122 patients (67.2%); it was similar when using ISV as a 1st or 2nd line treatment (60.5% vs 70.9%, respectively; p = 0.24). In multivariate analysis, both female sex (OR: 2.992; CI: 1.22-7.34) and induction phase of treatment (OR: 3.953; CI: 1.085-14.403) were predictive of a favorable response. At a median follow-up of 5 months, 43 (35.2%) patients were dead; the 1-year overall survival (OS) was 49.9%. In multivariate analysis, the response to ISV (OR: 0.103; CI: 0.041-0.262) and IFD refractoriness to previous antifungals (OR: 3.413; CI: 1.318-8.838) were statistically significant for OS. Adverse events (AEs) were reported in 15/122 patients (12.3%); grade 3-4 AEs were reported in 5 (4%) and led to ISV discontinuation. Our study confirms the safety and tolerability of ISV, also in diseases other than acute leukemia. Phase of hematological disease, gender and refractoriness to previous antifungals are the main predictive factors for the aforementioned response and outcome.
- Published
- 2019
13. Changes in the incidence of candidemia and related mortality in patients with hematologic malignancies in the last ten years. A SEIFEM 2015-B report
- Author
-
Pagano, Livio, primary, Dragonetti, Giulia, additional, Cattaneo, Chiara, additional, Marchesi, Francesco, additional, Veggia, Barbara, additional, Busca, Alessandro, additional, Candoni, Anna, additional, Prezioso, Lucia, additional, Criscuolo, Marianna, additional, Cesaro, Simone, additional, Delia, Mario, additional, Fanci, Rosa, additional, Stanzani, Marta, additional, Ferrari, Antonella, additional, Martino, Bruno, additional, Melillo, Lorella, additional, Nadali, Gianpaolo, additional, Simonetti, Edoardo, additional, Ballanti, Stelvio, additional, Picardi, Marco, additional, Castagnola, Carlo, additional, Decembrino, Nunzia, additional, Gazzola, Marco, additional, Fracchiolla, Nicola Stefano, additional, Mancini, Valentina, additional, Nosari, Annamaria, additional, Principe, Maria Ilaria Del, additional, Aversa, Franco, additional, and Tumbarello, Mario, additional
- Published
- 2017
- Full Text
- View/download PDF
14. Fludarabine, Cytarabine and Gentuzumab Ozogamicin (FLA-GO) as Salvage Therapy and Bridge to Transplant in Adult Relapsed Acute Myeloid Leukemia (AML) Patients
- Author
-
Principe, Maria Ilaria Del, primary
- Published
- 2017
- Full Text
- View/download PDF
15. 'Real-life' analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study.
- Author
-
Principe, Maria Ilaria Del, Dragonetti, Giulia, Verga, Luisa, Candoni, Anna, Marchesi, Francesco, Cattaneo, Chiara, Delia, Mario, Potenza, Leonardo, Farina, Francesca, Ballanti, Stelvio, Decembrino, Nunzia, Castagnola, Carlo, Nadali, Gianpaolo, Fanci, Rosa, Orciulo, Enrico, Veggia, Barbara, Offidani, Massimo, Melillo, Lorella, Manetta, Sara, and Tumbarello, Mario
- Subjects
- *
PREVENTIVE medicine , *ANTIFUNGAL agents , *CANCER chemotherapy , *ACUTE myeloid leukemia , *MYELOID leukemia - Abstract
Background: We evaluated the incidence of proven/probable invasive aspergillosis (IA) and the role of antifungal prophylaxis (AP) in a 'real-life' setting of patients with AML receiving intensive consolidation therapy.Methods: Cases of IA, observed during consolidation in adult/paediatric patients with AML between 2011 and 2015, were retrospectively collected in a multicentre Italian study.Results: Of 2588 patients, 56 (2.2%) developed IA [43 probable (1.7%) and 13 proven (0.5%)]. IA was diagnosed in 34 of 1137 (2.9%) patients receiving no AP and in 22 of 1451 (1.5%) who were given AP (P = 0.01). Number-needed-to-treat calculation indicates that, on average, 71 patients should have received AP (instead of no AP) for one additional patient to not have IA. Initial antifungal therapy was 'pre-emptive' in 36 (64%) patients and 'targeted' in 20 (36%) patients. A good response to first-line therapy was observed in 26 (46%) patients, mainly those who received AP [16 of 22 (73%) versus 10 of 34 (29%); P = 0.001]. The overall mortality rate and the mortality rate attributable to IA by day 120 were 16% and 9%, respectively. In multivariate analysis, age ≥60 years (OR = 12.46, 95% CI = 1.13-136.73; P = 0.03) and high-dose cytarabine treatment (OR = 10.56, 95% CI = 1.95-116.74; P = 0.04) independently affected outcome.Conclusions: In our experience, AP appears to prevent IA from occurring during consolidation. However, although the incidence of IA was low, mortality was not negligible among older patients. Further prospective studies should be carried out particularly in elderly patients treated with high-dose cytarabine to confirm our data and to identify subsets of individuals who may require AP. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
16. Changes in the incidence of candidemia and related mortality in patients with hematologic malignancies in the last ten years. A SEIFEM 2015-B report
- Author
-
Pagano, Livio, Dragonetti, Giulia, Cattaneo, Chiara, Marchesi, Francesco, Veggia, Barbara, Busca, Alessandro, Candoni, Anna, Prezioso, Lucia, Criscuolo, Marianna, Cesaro, Simone, Delia, Mario, Fanci, Rosa, Stanzani, Marta, Ferrari, Antonella, Martino, Bruno, Melillo, Lorella, Nadali, Gianpaolo, Simonetti, Edoardo, Ballanti, Stelvio, Picardi, Marco, Castagnola, Carlo, Decembrino, Nunzia, Gazzola, Marco, Fracchiolla, Nicola Stefano, Mancini, Valentina, Nosari, Annamaria, Principe, Maria Ilaria Del, Aversa, Franco, Tumbarello, Mario, Pagano, Livio (ORCID:0000-0001-8287-928X), Tumbarello, Mario (ORCID:0000-0002-9519-8552), Pagano, Livio, Dragonetti, Giulia, Cattaneo, Chiara, Marchesi, Francesco, Veggia, Barbara, Busca, Alessandro, Candoni, Anna, Prezioso, Lucia, Criscuolo, Marianna, Cesaro, Simone, Delia, Mario, Fanci, Rosa, Stanzani, Marta, Ferrari, Antonella, Martino, Bruno, Melillo, Lorella, Nadali, Gianpaolo, Simonetti, Edoardo, Ballanti, Stelvio, Picardi, Marco, Castagnola, Carlo, Decembrino, Nunzia, Gazzola, Marco, Fracchiolla, Nicola Stefano, Mancini, Valentina, Nosari, Annamaria, Principe, Maria Ilaria Del, Aversa, Franco, Tumbarello, Mario, Pagano, Livio (ORCID:0000-0001-8287-928X), and Tumbarello, Mario (ORCID:0000-0002-9519-8552)
- Abstract
na
- Published
- 2017
17. Hodgkin lymphoma in a mutated ZAP-70 negative B-cell Chronic Lymphocytic Leukemia patient
- Author
-
Niscola, Pasquale, Principe, Maria Ilaria Del, Palombi, Massimiliano, Fratoni, Stefano, Piccioni, Daniela, Maurillo, Luca, de Fabritiis, Paolo, Amadori, Sergio, and Del Poeta, Giovanni
- Published
- 2008
- Full Text
- View/download PDF
18. MRD-Directed Post-Remissional Therapy Dramatically Improves Outcome of Adult Patients with High Risk AML by Implementing Allogeneic Transplant Option
- Author
-
Buccisano, Francesco, primary, Maurillo, Luca, additional, Principe, Maria Ilaria Del, additional, Cerretti, Raffaella, additional, Consalvo, Maria Antonietta Irno, additional, Fraboni, Daniela, additional, Panetta, Paola, additional, Campagna, Selenia, additional, Ottaviani, Licia, additional, Sarlo, Chiara, additional, Angelis, Gottardo De, additional, Ditto, Concetta, additional, Caprio, Luigi Di, additional, Cefalo, Maria Giovanna, additional, Ammatuna, Emanuele, additional, Duranti, Fabio, additional, Coco, Francesco Lo, additional, Arcese, William, additional, Amadori, Sergio, additional, and Venditti, Adriano, additional
- Published
- 2010
- Full Text
- View/download PDF
19. Phase II Study of Bortezomib as a Single Agent In Patients with Relapsed/Refractory or De Novo Acute Myeloid Leukemia Unfit for Intensive Therapy
- Author
-
Sarlo, Chiara, primary, Cefalo, Maria Giovanna, additional, Ceresoli, Eleonora, additional, Ottaviani, Licia, additional, Campagna, Selenia, additional, Ditto, Concetta, additional, Caprio, Luigi Di, additional, Principe, Maria Ilaria Del, additional, Franchi, Annibale, additional, Maurillo, Luca, additional, Buccisano, Francesco, additional, Amadori, Sergio, additional, and Venditti, Adriano, additional
- Published
- 2010
- Full Text
- View/download PDF
20. Clinical Significance of CD69 Expression In Chronic Lymphocytic Leukemia
- Author
-
Poeta, Giovanni Del, primary, Principe, Maria Ilaria Del, additional, Bulian, Pietro, additional, Simotti, Cristina, additional, Buccisano, Francesco, additional, Luciano, Fabrizio, additional, Zucchetto, Antonella, additional, Ottaviani, Licia, additional, Maurillo, Luca, additional, Sarlo, Chiara, additional, Biagi, Annalisa, additional, Giannì, Laura, additional, Perrotti, Alessio Pio, additional, Venditti, Adriano, additional, Fabritiis, Paolo de, additional, Gattei, Valter, additional, and Amadori, Sergio, additional
- Published
- 2010
- Full Text
- View/download PDF
21. Normal Fish Cytogenetics and 13q Deletions Unveil Marked Biological and Clinical Heterogeneity In Chronic Lymphocytic Leukemia
- Author
-
Poeta, Giovanni Del, primary, Principe, Maria Ilaria Del, additional, Rossi, Francesca Maria, additional, Coletta, Angela, additional, Buccisano, Francesco, additional, Simotti, Cristina, additional, Cox, Maria Christina, additional, Luciano, Fabrizio, additional, Zucchetto, Antonella, additional, Maurillo, Luca, additional, Biagi, Annalisa, additional, Niscola, Pasquale, additional, Consalvo, Maria Antonietta Irno, additional, Perrotti, Alessio Pio, additional, Venditti, Adriano, additional, de Fabritiis, Paolo, additional, Gattei, Valter, additional, and Amadori, Sergio, additional
- Published
- 2010
- Full Text
- View/download PDF
22. Monitoring of minimal residual disease in acute myeloid leukemia
- Author
-
Buccisano, Francesco, primary, Maurillo, Luca, additional, Spagnoli, Alessandra, additional, Principe, Maria Ilaria Del, additional, Ceresoli, Eleonora, additional, Coco, Francesco Lo, additional, Arcese, William, additional, Amadori, Sergio, additional, and Venditti, Adriano, additional
- Published
- 2009
- Full Text
- View/download PDF
23. High CD79b Expression Predicts a Poor Outcome in B-Cell Chronic Lymphocytic Leukemia (B-CLL).
- Author
-
Poeta, Giovanni Del, primary, Principe, Maria Ilaria Del, primary, Zucchetto, Antonella, primary, Buccisano, Francesco, primary, Simotti, Cristina, primary, Maurillo, Luca, primary, Giannì, Laura, primary, Bulian, Pietro, primary, Venditti, Adriano, primary, Coletta, Angela, primary, Niscola, Pasquale, primary, de Fabritiis, Paolo, primary, Gattei, Valter, primary, and Amadori, Sergio, primary
- Published
- 2008
- Full Text
- View/download PDF
24. The Amount of Mitochondrial Apoptosis Exerts Prognostic Impact on Normal Karyotype Acute Myeloid Leukemia.
- Author
-
Poeta, Giovanni Del, primary, Principe, Maria Ilaria Del, primary, Buccisano, Francesco, primary, Maurillo, Luca, primary, Neri, Benedetta, primary, Ottaviani, Licia, primary, Luciano, Fabrizio, primary, Piccioni, Daniela, primary, Consalvo, Maria Irno, primary, Ammatuna, Emanuele, primary, Bruno, Antonio, primary, de Fabritiis, Paolo, primary, Gattei, Valter, primary, Venditti, Adriano, primary, Coco, Francesco Lo, primary, and Amadori, Sergio, primary
- Published
- 2008
- Full Text
- View/download PDF
25. Decisional Algorithm to Incorporate Hematopoietic Stem Cell Transplantation in the Management of Adult Patients with Acute Myeloid Leukaemia.
- Author
-
Buccisano, Francesco, primary, Maurillo, Luca, primary, Principe, Maria Ilaria Del, primary, Poeta, Giovanni Del, primary, Panetta, Paola, primary, Ammatuna, Emanuele, primary, Ottaviani, Licia, primary, Sarlo, Chiara, primary, Quaresima, Micol, primary, De Angelis, Gottardo, primary, Rizzo, Manuela, primary, Campagna, Selenia, primary, Coco, Francesco Lo, primary, Arcese, William, primary, Amadori, Sergio, primary, and Venditti, Adriano, primary
- Published
- 2008
- Full Text
- View/download PDF
26. Optimal Post-Remission Therapy for Flow-Cytometry Minimal Residual Disease Positive Patients with Acute Myeloid Leukemia.
- Author
-
Buccisano, Francesco, primary, Maurillo, Luca, primary, Gattei, Valter, primary, Poeta, Giovanni Del, primary, Principe, Maria Ilaria Del, primary, Fraboni, Fraboni, primary, Panetta, Paola, primary, Consalvo, Maria Irno, primary, Campagna, Selenia, primary, Giannì, Laura, primary, Ottaviani, Licia, primary, Postorino, Massimiliano, primary, De Fabritiis, Paolo, primary, Arcese, William, primary, Coco, Francesco Lo, primary, Amadori, Sergio, primary, and Venditti, Adriano, primary
- Published
- 2006
- Full Text
- View/download PDF
27. Signature of B‐CLL with different prognosis by Shrunken centroids of surface antigen expression profiling
- Author
-
Zucchetto, Antonella, primary, Sonego, Paolo, additional, Degan, Massimo, additional, Bomben, Riccardo, additional, Bo, Michele Dal, additional, Russo, Stefania, additional, Attadia, Vincenza, additional, Rupolo, Maurizio, additional, Buccisano, Francesco, additional, Principe, Maria Ilaria Del, additional, Poeta, Giovanni Del, additional, Pucillo, Carlo, additional, Colombatti, Alfonso, additional, Campanini, Renato, additional, and Gattei, Valter, additional
- Published
- 2004
- Full Text
- View/download PDF
28. CD90/Thy-1 is preferentially expressed on blast cells of high risk acute myeloid leukaemias*
- Author
-
Buccisano, Francesco, primary, Rossi, Francesca Maria, additional, Venditti, Adriano, additional, Poeta, Giovanni Del, additional, Cox, Maria Christina, additional, Abbruzzese, Elisabetta, additional, Rupolo, Maurizio, additional, Berretta, Massimiliano, additional, Degan, Massimo, additional, Russo, Stefania, additional, Tamburini, Anna, additional, Maurillo, Luca, additional, Principe, Maria Ilaria Del, additional, Postorino, Massimiliano, additional, Amadori, Sergio, additional, and Gattei, Valter, additional
- Published
- 2004
- Full Text
- View/download PDF
29. A shorter time to the first treatment may be predicted by the absolute number of regulatory T-cells in patients with Rai stage 0 chronic lymphocytic leukemia.
- Author
-
D'Arena, Giovanni, D'Auria, Fiorella, Simeon, Vittorio, Laurenti, Luca, Deaglio, Silvia, Mansueto, Giovanna, Principe, Maria Ilaria Del, Statuto, Teodora, Pietrantuono, Giuseppe, Guariglia, Roberto, Innocenti, Idanna, Martorelli, Maria Carmen, Villani, Oreste, De Feo, Vincenzo, Poeta, Giovanni Del, and Musto, Pellegrino
- Published
- 2012
- Full Text
- View/download PDF
30. Advances in the treatment of elderly and frail patients with acute myeloid leukemia
- Author
-
Amadori, Sergio, Principe, Maria Ilaria Del, and Venditti, Adriano
- Abstract
Significant advances have been made in the treatment of younger patients with acute myeloid leukemia over the past 3 decades, but prognosis in the elderly has remained dismal, with median survival times of only a few months. Although a small percentage of older patients may be cured by standard chemotherapy, it is clear that several aspects of frontline management require improvement and novel approaches are urgently needed. This review focuses on treatment options currently available to older patients with acute myeloid leukemia, with an emphasis on new therapeutics.
- Published
- 2014
- Full Text
- View/download PDF
31. ZAP‐70 expression in B‐cell chronic lymphocytic leukemia: Evaluation by external (isotypic) or internal (T/NK cells) controls and correlation with IgVH mutations
- Author
-
Zucchetto, Antonella, Bomben, Riccardo, Bo, Michele Dal, Nanni, Paola, Bulian, Pietro, Rossi, Francesca Maria, Principe, Maria Ilaria Del, Santini, Simone, Poeta, Giovanni Del, Degan, Massimo, and Gattei, Valter
- Abstract
Expression of T cell specific zeta‐associated protein 70 (ZAP‐70) by B‐cell chronic lymphocytic leukemia (B‐CLL) cells, as investigated by flow cytometry, has both prognostic relevance and predictive power as surrogate for immunoglobulin heavy chain variable region (IgVH) mutations, although a standardization of the cytometric protocol is still lacking.Flow cytometric analyses for ZAP‐70 were performed in peripheral blood samples from 145 B‐CLL (124 with IgVH mutations) by a standard three‐color protocol. Identification of ZAP‐70+ cell population was based on an external negative control, i.e., the isotypic control (ISO method) or an internal positive control, i.e., the population of residual normal T/NK cells (TNK method). A comparison between these two approaches was performed.While 86/145 cases were concordant as for ZAP‐70 expression according to the two methods (ISO+TNK+ or ISO−TNK−), 59/145 cases had discordant ZAP‐70 expression, mainly (56/59) showing a ISO+TNK− profile. These latter cases express higher levels of ZAP‐70 in their normal T cell component. Moreover, discordant ISO+TNK− cases had a IgVH gene mutation profile similar to that of concordantly positive cases and different from ZAP‐70 concordantly negative B‐CLL.Analysis of ZAP‐70 expression by B‐CLL cells by using the ISO method allows to overcome the variability in the expression of ZAP‐70 by residual T cells and yields a better correlation with IgVH gene mutations. A receiver operating characteristic analysis suggests to employ a higher cut‐off than the commonly used 20%. A parallel evaluation of the prognostic value of ZAP‐70 expression, as determined according to the ISO and TNK methods, is still needed. © 2006 International Society for Analytical Cytology
- Published
- 2006
- Full Text
- View/download PDF
32. Thoracic Cord Compression Caused by Epidural Extramedullary Hematopoiesis During Erythroid-Stimulating Agent Therapy in Two Patients With Myelodysplastic Syndromes.
- Author
-
Neri, Benedetta, Masala, Salvatore, Mauriello, Alessandro, Principe, Maria Ilaria Del, Ditto, Concetta, Sarlo, Chiara, Cefalo, Mariagiovanna, Di Caprio, Luigi, Loreni, Giorgio, Cicconi, Laura, Amadori, Sergio, and Venditti, Adriano
- Published
- 2013
- Full Text
- View/download PDF
33. COVID-19 infection in adult patients with hematological malignancies:a European Hematology Association Survey (EPICOVIDEHA)
- Author
-
Pagano, Livio, Salmanton-García, Jon, Marchesi, Francesco, Busca, Alessandro, Corradini, Paolo, Hoenigl, Martin, Klimko, Nikolai, Koehler, Philipp, Pagliuca, Antonio, Passamonti, Francesco, Verga, Luisa, Víšek, Benjamin, Ilhan, Osman, Nadali, Gianpaolo, Weinbergerová, Barbora, Córdoba-Mascuñano, Raúl, Marchetti, Monia, Collins, Graham P., Farina, Francesca, Cattaneo, Chiara, Cabirta, Alba, Gomes-Silva, Maria, Itri, Federico, van Doesum, Jaap, Ledoux, Marie-Pierre, Čerňan, Martin, Jakšić, Ozren, Duarte, Rafael F., Magliano, Gabriele, Omrani, Ali S., Fracchiolla, Nicola S., Kulasekararaj, Austin, Valković, Toni, Poulsen, Christian Bjørn, Machado, Marina, Glenthøj, Andreas, Stoma, Igor, Ráčil, Zdeněk, Piukovics, Klára, Navrátil, Milan, Emarah, Ziad, Sili, Uluhan, Maertens, Johan, Blennow, Ola, Bergantim, Rui, García-Vidal, Carolina, Prezioso, Lucia, Guidetti, Anna, del Principe, Maria Ilaria, Popova, Marina, de Jonge, Nick, Ormazabal-Vélez, Irati, Fernández, Noemí, Falces-Romero, Iker, Cuccaro, Annarosa, Meers, Stef, Buquicchio, Caterina, Antić, Darko, Al-Khabori, Murtadha, García-Sanz, Ramón, Biernat, Monika M., Tisi, Maria Chiara, Sal, Ertan, Rahimli, Laman, Čolović, Natasa, Schönlein, Martin, Calbacho, Maria, Tascini, Carlo, Miranda-Castillo, Carolina, Khanna, Nina, Méndez, Gustavo-Adolfo, Petzer, Verena, Novák, Jan, Besson, Caroline, Duléry, Rémy, Lamure, Sylvain, Nucci, Marcio, Zambrotta, Giovanni, Žák, Pavel, Seval, Guldane Cengiz, Bonuomo, Valentina, Mayer, Jiří, López-García, Alberto, Sacchi, Maria Vittoria, Booth, Stephen, Ciceri, Fabio, Oberti, Margherita, Salvini, Marco, Izuzquiza, Macarena, Nunes-Rodrigues, Raquel, Ammatuna, Emanuele, Obr, Aleš, Herbrecht, Raoul, Núñez-Martín-Buitrago, Lucía, Mancini, Valentina, Shwaylia, Hawraa, Sciumè, Mariarita, Essame, Jenna, Nygaard, Marietta, Batinić, Josip, Gonzaga, Yung, Regalado-Artamendi, Isabel, Karlsson, Linda Katharina, Shapetska, Maryia, Hanakova, Michaela, El-Ashwah, Shaimaa, Borbényi, Zita, Çolak, Gökçe Melis, Nordlander, Anna, Dragonetti, Giulia, Maraglino, Alessio Maria Edoardo, Rinaldi, Amelia, De Ramón-Sánchez, Cristina, Cornely, Oliver A., Finizio, Olimpia, Fazzi, Rita, Sapienza, Giuseppe, Chauchet, Adrien, Van Praet, Jens, Prattes, Juergen, Dargenio, Michelina, Rossi, Cédric, Shirinova, Ayten, Malak, Sandra, Tafuri, Agostino, Ommen, Hans-Beier, Bologna, Serge, Khedr, Reham Abdelaziz, Choquet, Sylvain, Joly, Bertrand, Ceesay, M. Mansour, Philippe, Laure, Kho, Chi Shan, Desole, Maximilian, Tsirigotis, Panagiotis, Otašević, Vladimir, Borducchi, Davimar M. M., Antoniadou, Anastasia, Gaziev, Javid, Almaslamani, Muna A., García-Poutón, Nicole, Paterno, Giovangiacinto, Torres-López, Andrea, Tarantini, Giuseppe, Mellinghoff, Sibylle, Gräfe, Stefanie, Börschel, Niklas, Passweg, Jakob, Merelli, Maria, Barać, Aleksandra, Wolf, Dominik, Shaikh, Mohammad Usman, Thiéblemont, Catherine, Bernard, Sophie, Funke, Vaneuza Araújo Moreira, Daguindau, Etienne, Khostelidi, Sofya, Nucci, Fabio Moore, Martín-González, Juan-Alberto, Landau, Marianne, Soussain, Carole, Laureana, Cécile, Lacombe, Karine, Kohn, Milena, Aliyeva, Gunay, Piedimonte, Monica, Fouquet, Guillemette, Rêgo, Mayara, Hoell-Neugebauer, Baerbel, Cartron, Guillaume, Pinto, Fernando, Alburquerque, Ana Munhoz, Passos, Juliana, Yilmaz, Asu Fergun, Redondo-Izal, Ana-Margarita, Altuntaş, Fevzi, Heath, Christopher, Kolditz, Martin, Schalk, Enrico, Guolo, Fabio, Karthaus, Meinolf, Della Pepa, Roberta, Vinh, Donald, Noël, Nicolas, Deau Fischer, Bénédicte, Drenou, Bernard, Mitra, Maria Enza, Meletiadis, Joseph, Bilgin, Yavuz M., Jindra, Pavel, Espigado, Ildefonso, Drgoňa, Ľuboš, Serris, Alexandra, Di Blasi, Roberta, Ali, Natasha, EPICOVIDEHA working group, [missing], Pagano, Livio, Salmanton-Garcia, Jon, Marchesi, Francesco, Busca, Alessandro, Corradini, Paolo, Hoenigl, Martin, Klimko, Nikolai, Koehler, Philipp, Pagliuca, Antonio, Passamonti, Francesco, Verga, Luisa, Visek, Benjamin, Ilhan, Osman, Nadali, Gianpaolo, Weinbergerova, Barbora, Cordoba-Mascunano, Raul, Marchetti, Monia, Collins, Graham P., Farina, Francesca, Cattaneo, Chiara, Cabirta, Alba, Gomes-Silva, Maria, Itri, Federico, van Doesum, Jaap, Ledoux, Marie-Pierre, Cernan, Martin, Jaksic, Ozren, Duarte, Rafael F., Magliano, Gabriele, Omrani, Ali S., Fracchiolla, Nicola S., Kulasekararaj, Austin, Valkovic, Toni, Poulsen, Christian Bjorn, Machado, Marina, Glenthoj, Andreas, Stoma, Igor, Racil, Zdenek, Piukovics, Klara, Navratil, Milan, Emarah, Ziad, Sili, Uluhan, Maertens, Johan, Blennow, Ola, Bergantim, Rui, Garcia-Vidal, Carolina, Prezioso, Lucia, Guidetti, Anna, del Principe, Maria Ilaria, Popova, Marina, de Jonge, Nick, Ormazabal-Velez, Irati, Fernandez, Noemi, Falces-Romero, Iker, Cuccaro, Annarosa, Meers, Stef, Buquicchio, Caterina, Antic, Darko, Al-Khabori, Murtadha, Garcia-Sanz, Ramon, Biernat, Monika M., Tisi, Maria Chiara, Sal, Ertan, Rahimli, Laman, Colovic, Natasa, Schonlein, Martin, Calbacho, Maria, Tascini, Carlo, Miranda-Castillo, Carolina, Khanna, Nina, Mendez, Gustavo-Adolfo, Petzer, Verena, Novak, Jan, Besson, Caroline, Dulery, Remy, Lamure, Sylvain, Nucci, Marcio, Zambrotta, Giovanni, Zak, Pavel, Seval, Guldane Cengiz, Bonuomo, Valentina, Mayer, Jiri, Lopez-Garcia, Alberto, Sacchi, Maria Vittoria, Booth, Stephen, Ciceri, Fabio, Oberti, Margherita, Salvini, Marco, Izuzquiza, Macarena, Nunes-Rodrigues, Raquel, Ammatuna, Emanuele, Obr, Ales, Herbrecht, Raoul, Nunez-Martin-Buitrago, Lucia, Mancini, Valentina, Shwaylia, Hawraa, Sciume, Mariarita, Essame, Jenna, Nygaard, Marietta, Batinic, Josip, Gonzaga, Yung, Regalado-Artamendi, Isabel, Karlsson, Linda Katharina, Shapetska, Maryia, Hanakova, Michaela, El-Ashwah, Shaimaa, Borbenyi, Zita, Colak, Gokce Melis, Nordlander, Anna, Dragonetti, Giulia, Maraglino, Alessio Maria Edoardo, Rinaldi, Amelia, De Ramon-Sanchez, Cristina, Cornely, Oliver A., Pagano, L., Salmanton-Garcia, J., Marchesi, F., Busca, A., Corradini, P., Hoenigl, M., Klimko, N., Koehler, P., Pagliuca, A., Passamonti, F., Verga, L., Visek, B., Ilhan, O., Nadali, G., Weinbergerova, B., Cordoba-Mascunano, R., Marchetti, M., Collins, G. P., Farina, F., Cattaneo, C., Cabirta, A., Gomes-Silva, M., Itri, F., van Doesum, J., Ledoux, M. -P., Cernan, M., Jaksic, O., Duarte, R. F., Magliano, G., Omrani, A. S., Fracchiolla, N. S., Kulasekararaj, A., Valkovic, T., Poulsen, C. B., Machado, M., Glenthoj, A., Stoma, I., Racil, Z., Piukovics, K., Navratil, M., Emarah, Z., Sili, U., Maertens, J., Blennow, O., Bergantim, R., Garcia-Vidal, C., Prezioso, L., Guidetti, A., del Principe, M. I., Popova, M., de Jonge, N., Ormazabal-Velez, I., Fernandez, N., Falces-Romero, I., Cuccaro, A., Meers, S., Buquicchio, C., Antic, D., Al-Khabori, M., Garcia-Sanz, R., Biernat, M. M., Tisi, M. C., Sal, E., Rahimli, L., Colovic, N., Schonlein, M., Calbacho, M., Tascini, C., Miranda-Castillo, C., Khanna, N., Mendez, G. -A., Petzer, V., Novak, J., Besson, C., Dulery, R., Lamure, S., Nucci, M., Zambrotta, G., Zak, P., Seval, G. C., Bonuomo, V., Mayer, J., Lopez-Garcia, A., Sacchi, M. V., Booth, S., Ciceri, F., Oberti, M., Salvini, M., Izuzquiza, M., Nunes-Rodrigues, R., Ammatuna, E., Obr, A., Herbrecht, R., Nunez-Martin-Buitrago, L., Mancini, V., Shwaylia, H., Sciume, M., Essame, J., Nygaard, M., Batinic, J., Gonzaga, Y., Regalado-Artamendi, I., Karlsson, L. K., Shapetska, M., Hanakova, M., El-Ashwah, S., Borbenyi, Z., Colak, G. M., Nordlander, A., Dragonetti, G., Maraglino, A. M. E., Rinaldi, A., De Ramon-Sanchez, C., Cornely, O. A., Finizio, O., Fazzi, R., Sapienza, G., Chauchet, A., Van Praet, J., Prattes, J., Dargenio, M., Rossi, C., Shirinova, A., Malak, S., Tafuri, A., Ommen, H. -B., Bologna, S., Khedr, R. A., Choquet, S., Joly, B., Ceesay, M. M., Philippe, L., Kho, C. S., Desole, M., Tsirigotis, P., Otasevic, V., Borducchi, D. M. M., Antoniadou, A., Gaziev, J., Almaslamani, M. A., Garcia-Pouton, N., Paterno, G., Torres-Lopez, A., Tarantini, G., Mellinghoff, S., Grafe, S., Borschel, N., Passweg, J., Merelli, M., Barac, A., Wolf, D., Shaikh, M. U., Thieblemont, C., Bernard, S., Funke, V. A. M., Daguindau, E., Khostelidi, S., Nucci, F. M., Martin-Gonzalez, J. -A., Landau, M., Soussain, C., Laureana, C., Lacombe, K., Kohn, M., Aliyeva, G., Piedimonte, M., Fouquet, G., Rego, M., Hoell-Neugebauer, B., Cartron, G., Pinto, F., Alburquerque, A. M., Passos, J., Yilmaz, A. F., Redondo-Izal, A. -M., Altuntas, F., Heath, C., Kolditz, M., Schalk, E., Guolo, F., Karthaus, M., Della Pepa, R., Vinh, D., Noel, N., Deau Fischer, B., Drenou, B., Mitra, M. E., Meletiadis, J., Bilgin, Y. M., Jindra, P., Espigado, I., Drgona, L., Serris, A., Di Blasi, R., Ali, N., Stem Cell Aging Leukemia and Lymphoma (SALL), Salvy-Córdoba, Nathalie, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università cattolica del Sacro Cuore = Catholic University of the Sacred Heart [Roma] (Unicatt), University Hospital of Cologne [Cologne], Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, IFO - Istituto Nazionale Tumori Regina Elena [Roma] (IRE), Città della Salute e della Scienza University-Hospital, IRCCS Istituto Nazionale dei Tumori [Milano], University of California [San Diego] (UC San Diego), University of California (UC), Medical University of Graz, Odessa National I.I.Mechnikov University, Faculty of Medicine [Cologne], University Hospital of Cologne [Cologne]-University of Cologne, King's College Hospital (KCH), Universitá degli Studi dell’Insubria = University of Insubria [Varese] (Uninsubria), Dipartimento di Medicina e Chirurgia = School of Medicine and Surgery [Monza], Università degli Studi di Milano-Bicocca = University of Milano-Bicocca (UNIMIB), Faculty of Medicine in Hradec Kralove [Republique Tchèque], Charles University [Prague] (CU), Ankara University School of Medicine [Turkey], Azienda Ospedaliera Universitaria Integrata of Verona, Masaryk University [Brno] (MUNI), Fundación Jiménez Díaz, Fundacion Jimenez Diaz [Madrid] (FJD), Ospedale SS Antonio e Biagio e Cesare Arrigo, Churchill Hospital Oxford Centre for Haematology, IRCCS San Raffaele Scientific Institute [Milan, Italie], ASST Spedali Civili of Brescia, Vall d'Hebron Institute of Oncology [Barcelone] (VHIO), Vall d'Hebron University Hospital [Barcelona], Universitat Autònoma de Barcelona (UAB), Instituto Português de Oncologia de Lisboa Francisco Gentil, Ospedale San Luigi Gonzaga, University Medical Center Groningen [Groningen] (UMCG), Institut de Cancérologie de Strasbourg Europe (ICANS), Palacky University Olomouc, Zagreb School of Medicine [Zagreb, Croatia] (Dubrava University Hospital), University of Zagreb, Hospital Universitario Puerta de Hierro-Majadahonda [Madrid, Spain], ASST Great Metropolitan Niguarda / ASST Grande Ospedale Metropolitano Niguarda [Milan, Italia], Hamad Medical Corporation [Doha, Qatar], Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, University of Rijeka, Croatian Cooperative Group for Hematological Diseases (CROHEM), Zealand University Hospital [Roskilde, Denmark], Hospital General Universitario 'Gregorio Marañón' [Madrid], Department of Clinical Microbiology [Rigshospitalet], Rigshospitalet [Copenhagen], Copenhagen University Hospital-Copenhagen University Hospital, Homieĺ State Medical University (GSMU), Institute of Hematology and Blood Transfusion [Prague, Czech Republic], University of Szeged [Szeged], University Hospital Ostrava, Mansoura University [Egypt], Marmara University [Kadıköy - İstanbul], Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven), Karolinska University Hospital [Stockholm], Instituto de Investigação e Inovação em Saúde (I3S), Universidade do Porto = University of Porto, Instituto de Patologia e Imunologia Molecular da Universidade do Porto (IPATIMUP), Hospital de São João [Porto], Faculdade de Medicina da Universidade do Porto (FMUP), Clinic Barcelona Hospital Universitari, Department of Public Health and Cell Biology, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy, Pavlov First Saint Petersburg State Medical University [St. Petersburg], Vrije Universiteit Medical Centre (VUMC), Vrije Universiteit Amsterdam [Amsterdam] (VU), Complejo Hospitalario de Navarra, Hospital Universitario Marqués de Valdecilla [Santander], La Paz University Hospital, Azienda Usl Toscana centro [Firenze], AZ Klina, Clinical Center of Serbia (KCS), University of Belgrade [Belgrade], Sultan Qaboos University Hospital, Partenaires INRAE, Hospital Universitario de Salamanca, Servicio de Haematologia, Centro de Investigación del Cáncer-IBMCC (USAL-CSIC), University of Wrocław [Poland] (UWr), San Bortolo Hospital, Universitaetsklinikum Hamburg-Eppendorf = University Medical Center Hamburg-Eppendorf [Hamburg] (UKE), Hospital Universitario 12 de Octubre [Madrid], Azienda Sanitaria Universitaria Friuli Centrale (ASU FC), Universidad Rey Juan Carlos [Madrid] (URJC), University of Basel (Unibas), Innsbruck Medical University = Medizinische Universität Innsbruck (IMU), University Hospital Kralovské Vinohrady, Centre Hospitalier de Versailles André Mignot (CHV), Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Institut de Génétique Moléculaire de Montpellier (IGMM), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Département Hématologie biologique [CHRU Montpellier], Pôle Biologie-Pathologie [CHRU Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Universidade Federal do Estado do Rio de Janeiro (UNIRIO), San Gerardo Hospital of Monza, Oxford NIHR Biomedical Research Centre, IRCCS Ospedale San Raffaele [Milan, Italy], Assi Sette Llaghi Varese, Instituto Português de Oncologia do Porto / Portuguese Oncology Institute of Porto (IPO Porto), University Hospital Olomouc [Czech Republic], ASST Grande Ospedale Metropolitano Niguarda, University Hospital Centre Zagreb, Instituto Nacional do Câncer, Copenhagen University Hospital, Republican Scientific and Practical Center (RSPC) for organ and Tissue Transplantation, Minsk, Republican Scientific and Practical Center (RSPC) for Organ and Transplantation, German Centre for Infection Research (DZIF), Gilead Sciences, Pagano, Livio [0000-0001-8287-928X], Salmanton-García, Jon [0000-0002-6766-8297], Marchesi, Francesco [0000-0001-6353-2272], Busca, Alessandro [0000-0001-5361-5613], Corradini, Paolo [0000-0002-9186-1353], Hoenigl, Martin [0000-0002-1653-2824], Klimko, Nikolay [0000-0001-6095-7531], Koehler, Philipp [0000-0002-7386-7495], Pagliuca, Antonio [0000-0003-2519-0333], Passamonti, Francesco [0000-0001-8068-5289], Verga, Luisa [0000-0003-1142-8435], Víšek, Benjamin [0000-0001-8268-452X], Ilhan, Osman [0000-0003-1665-372X], Weinbergerová, Barbora [0000-0001-6460-2471], Córdoba, Raúl [0000-0002-7654-8836], Marchetti, Monia [0000-0001-7615-0572], Farina, Francesca [0000-0002-5124-6970], Cattaneo, Chiara [0000-0003-0031-3237], Cabirta, Alba [0000-0001-7198-8894], Gomes-Silva, Maria [0000-0002-6993-2450], Itri, Federico [0000-0002-3532-5281], Doesum, Jaap van [0000-0003-0214-3219], Ledoux, Marie-Pierre [0000-0002-3261-3616], Čerňan, Martin [0000-0003-2345-1229], Jakšić, Ozren [0000-0003-4026-285X], Magliano, Gabriel [0000-0002-9129-1530], Omrani, Ali S. [0000-0001-5309-6358], Fracchiolla, Nicola S. [0000-0002-8982-8079], Kulasekararaj, Austin G. [0000-0003-3180-3570], Valković, Toni [0000-0001-6083-8815], Poulsen, Christian Bjørn [0000-0001-9785-1378], Machado, Marina [0000-0002-8370-2248], Glenthøj, Andrea [0000-0003-2082-0738], Stoma, Igor [0000-0003-0483-7329], Ráčil, Zdeněk [0000-0003-3511-4596], Piukovics, Klára [0000-0003-4480-3131], Emarah, Ziad [0000-0003-0622-2598], Sili, Uluhan [0000-0002-9939-9298], Maertens, Johan [0000-0003-4257-5980], Bergantim, Rui [0000-0002-7811-9509], García-Vidal, Carolina [0000-0002-8915-0683], Prezioso, Lucia [0000-0003-1660-4960], Principe, Maria Ilaria del [0000-0002-3958-0669], Popova, Marina [0000-0001-8536-5495], Jonge, Nick de [0000-0002-9901-0887], Ormazabal-Vélez, Irati [0000-0003-1141-5546], Falces-Romero, Iker [0000-0001-5888-7706], Cuccaro, Annarosa [0000-0002-0237-1839], Meers, Stef [0000-0003-1754-2175], Buquicchio, Caterina [0000-0002-3683-5953], Antić, Darko [0000-0002-2608-1342], Al-Khabori, Murtadha [0000-0002-2937-8838], García-Sanz, Ramón [0000-0003-4120-2787], Biernat, Monika [0000-0003-3161-3398], Tisi, Maria Chiara [0000-0001-8231-6700], Sal, Ertan [0000-0003-2761-2675], Rahimli, Laman [0000-0003-2266-445X], Schönlein, Martin [0000-0002-1010-0975], Calbacho, María [0000-0001-8106-4863], Tascini, Carlo [0000-0001-9625-6024], Miranda-Castillo, Carolina [0000-0001-8763-9576], Khanna, Nina [0000-0002-2642-419X], Méndez, Gustavo-Adolfo [0000-0003-0514-7004], Petzer, Verena [0000-0002-9205-1440], Besson, Caroline [0000-0003-4364-7173], Duléry, Rémy [0000-0002-5024-1713], Lamure, Sylvain [0000-0001-5980-305X], Nucci, Marcio [0000-0003-4867-0014], Zambrotta, Giovanni [0000-0002-8612-2994], Žák, Pavel [0000-0003-4465-5343], Cengiz Seval, Guldane [0000-0001-9433-2054], Bonuomo, Valentina [0000-0001-6491-8337], Mayer, Jiří [0000-0003-0567-9887], López-García, Alberto [0000-0002-5354-5261], Sacchi, Maria Vittoria [0000-0001-8133-3357], Booth, Stephen [0000-0003-2687-0234], Ciceri, Fabio [0000-0003-0873-0123], Nunes-Rodrigues, Raquel [0000-0002-8347-4281], Ammatuna, Emanuele [0000-0001-8247-4901], Obr, Aleš [0000-0002-6758-3074], Herbrecht, Raoul [0000-0002-9381-4876], Shwaylia, Hawraa [0000-0002-4098-6092], Sciumè, Mariarita [0000-0001-7958-4966], Essame, Jenna [0000-0003-0926-5577], Batinić, Josip [0000-0001-5595-9911], Gonzaga, Yung [0000-0003-1416-2118], Regalado-Artamendi, Isabel [0000-0002-9673-9015], Karlsson, Linda Katharina [0000-0003-3317-7550], Shapetska, Maryia [0000-0002-1223-9161], El-Ashwah, Shaimaa [0000-0003-2210-1534], Çolak, Gökçe Melis [0000-0002-7662-7454], Dragonetti, Giulia [0000-0003-1775-6333], Rinaldi, Amelia [0000-0002-8211-5076], Ramón, Cristina de [0000-0002-8167-6410], Cornely, Oliver A. [0000-0001-9599-3137], Institut Català de la Salut, [Pagano L] Hematology, Fondazione Policlinico Universitario Agostino Gemelli - IRCCS – Università Cattolica del Sacro Cuore, Rome, Italy. Università Cattolica del Sacro Cuore, Rome, Italy. [Salmanton-García J] Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Excellence Center for Medical Mycology (ECMM), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany. Cologne Excellence Cluster On Cellular Stress Responses in Aging Associated Diseases (CECAD), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany. [Marchesi F] Hematology and Stem Cell Transplant Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy. [Busca A] Stem Cell Transplant Center, AOU Citta’ Della Salute E Della Scienza, Turin, Italy. [Corradini P] University of Milan and Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy. [Hoenigl M] Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, San Diego, CA, USA. Clinical and Translational Fungal Working Group, University of California San Diego, La Jolla, CA, USA. Section of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Medical University of Graz, Graz, Austria. [Cabirta A, Izuzquiza M] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain, Vall d'Hebron Barcelona Hospital Campus, Hematology, Salmanton-García, Jon, Klimko, Nikolay, Víšek, Benjamin, Weinbergerová, Barbora, Córdoba, Raúl, Doesum, Jaap van, Čerňan, Martin, Jakšić, Ozren, Magliano, Gabriel, Kulasekararaj, Austin G., Valković, Toni, Poulsen, Christian Bjørn, Glenthøj, Andrea, Ráčil, Zdeněk, Piukovics, Klára, García-Vidal, Carolina, Principe, Maria Ilaria del, Jonge, Nick de, Ormazabal-Vélez, Irati, Antić, Darko, García-Sanz, Ramón, Biernat, Monika, Schönlein, Martin, Calbacho, María, Méndez, Gustavo-Adolfo, Duléry, Rémy, Žák, Pavel, Cengiz Seval, Guldane, Mayer, Jiří, López-García, Alberto, Obr, Aleš, Sciumè, Mariarita, Batinić, Josip, Çolak, Gökçe Melis, Ramón, Cristina de, and Universidad de Sevilla. Departamento de Medicina
- Subjects
[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/Hematology ,Male ,Cancer Research ,MESH: Registries ,Epidemiology ,MESH: Hospitalization ,Hematological malignancies ,Otros calificadores::Otros calificadores::/complicaciones [Otros calificadores] ,MESH: Aged, 80 and over ,MESH: Risk Factors ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Risk Factors ,Malalties - Factors de risc ,Risk of mortality ,Medicine and Health Sciences ,virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES] ,80 and over ,Medicine ,MESH: COVID-19 ,Registries ,Sang - Malalties - Complicacions ,RC254-282 ,Cause of death ,BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Interna medicina ,MESH: Aged ,Aged, 80 and over ,Hematology ,MESH: Middle Aged ,Mortality rate ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Myeloid leukemia ,Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES] ,[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology ,Middle Aged ,CANCER ,Europe ,Hospitalization ,Intensive Care Units ,Oncology ,MESH: Young Adult ,Hematologic Neoplasms ,[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Female ,BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Infektologija ,Life Sciences & Biomedicine ,Adult ,medicine.medical_specialty ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,COVID-19 ,EHA ,Pandemic ,Aged ,Humans ,SARS-CoV-2 ,Young Adult ,técnicas de investigación::métodos epidemiológicos::estadística como asunto::probabilidad::riesgo::factores de riesgo [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,[SDV.CAN] Life Sciences [q-bio]/Cancer ,Intensive care ,Internal medicine ,Diseases of the blood and blood-forming organs ,MESH: SARS-CoV-2 ,neoplasias::neoplasias por localización::neoplasias hematológicas [ENFERMEDADES] ,Molecular Biology ,BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Internal Medicine ,pandemic ,hematological malignancies ,epidemiology ,MESH: Humans ,Science & Technology ,business.industry ,Myelodysplastic syndromes ,Research ,MESH: Adult ,Neoplasms::Neoplasms by Site::Hematologic Neoplasms [DISEASES] ,medicine.disease ,BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Infectology ,Settore MED/15 ,MESH: Male ,Settore MED/15 - MALATTIE DEL SANGUE ,[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie ,COVID-19 (Malaltia) - Diagnòstic ,MESH: Intensive Care Units ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,MESH: Europe ,RC633-647.5 ,business ,MESH: Female ,Other subheadings::Other subheadings::/complications [Other subheadings] ,MESH: Hematologic Neoplasms - Abstract
Background Patients with hematological malignancies (HM) are at high risk of mortality from SARS-CoV-2 disease 2019 (COVID-19). A better understanding of risk factors for adverse outcomes may improve clinical management in these patients. We therefore studied baseline characteristics of HM patients developing COVID-19 and analyzed predictors of mortality. Methods The survey was supported by the Scientific Working Group Infection in Hematology of the European Hematology Association (EHA). Eligible for the analysis were adult patients with HM and laboratory-confirmed COVID-19 observed between March and December 2020. Results The study sample includes 3801 cases, represented by lymphoproliferative (mainly non-Hodgkin lymphoma n = 1084, myeloma n = 684 and chronic lymphoid leukemia n = 474) and myeloproliferative malignancies (mainly acute myeloid leukemia n = 497 and myelodysplastic syndromes n = 279). Severe/critical COVID-19 was observed in 63.8% of patients (n = 2425). Overall, 2778 (73.1%) of the patients were hospitalized, 689 (18.1%) of whom were admitted to intensive care units (ICUs). Overall, 1185 patients (31.2%) died. The primary cause of death was COVID-19 in 688 patients (58.1%), HM in 173 patients (14.6%), and a combination of both COVID-19 and progressing HM in 155 patients (13.1%). Highest mortality was observed in acute myeloid leukemia (199/497, 40%) and myelodysplastic syndromes (118/279, 42.3%). The mortality rate significantly decreased between the first COVID-19 wave (March–May 2020) and the second wave (October–December 2020) (581/1427, 40.7% vs. 439/1773, 24.8%, p value, EPICOVIDEHA has received funds from Optics COMMITTM (COVID-19 Unmet Medical Needs and Associated Research Extension) COVID-19 RFP program by GILEAD Science, United States (Project 2020-8223).
- Published
- 2021
- Full Text
- View/download PDF
34. COVID-19 infection in acute lymphoblastic leukemia over 15 months of the pandemic. A Campus ALL report
- Author
-
Sabina Chiaretti, Massimiliano Bonifacio, Roberta Agrippino, Fabio Giglio, Mario Annunziata, Antonio Curti, Maria Ilaria Del Principe, Prassede Salutari, Mariarita Sciumè, Mario Delia, Marco Armenio, Valentina Mancini, Antonino Mulè, Francesco Grimaldi, Giovanna Rege-Cambrin, Lidia Santoro, Federico Lussana, Patrizia Chiusolo, Crescenza Pasciolla, Anna Maria Scattolin, Marco Cerrano, Maria Ciccone, Marzia Defina, Fabio Forghieri, Carla Mazzone, Matteo Piccini, Felicetto Ferrara, Giovanni Pizzolo, Robin Foà, Chiaretti, Sabina, Bonifacio, Massimiliano, Agrippino, Roberta, Giglio, Fabio, Annunziata, Mario, Curti, Antonio, Principe, Maria Ilaria Del, Salutari, Prassede, Sciumè, Mariarita, Delia, Mario, Armenio, Marco, Mancini, Valentina, Mulè, Antonino, Grimaldi, Francesco, Rege-Cambrin, Giovanna, Santoro, Lidia, Lussana, Federico, Chiusolo, Patrizia, Pasciolla, Crescenza, Scattolin, Anna Maria, Cerrano, Marco, Ciccone, Maria, Defina, Marzia, Forghieri, Fabio, Mazzone, Carla, Piccini, Matteo, Ferrara, Felicetto, Pizzolo, Giovanni, and Foà, Robin
- Subjects
Pandemic ,ables ,source of infection ,geographical distribution ,COVID-19 ,Humans ,Pandemics ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Hematology ,Settore MED/15 ,Settore MED/15 - Malattie del Sangue ,Human - Published
- 2021
35. Changes in the incidence of candidemia and related mortality in patients with hematologic malignancies in the last ten years. A SEIFEM 2015-B report
- Author
-
Edoardo Simonetti, Mario Tumbarello, Rosa Fanci, Carlo Castagnola, Nunzia Decembrino, Mario Delia, Antonella Ferrari, Lorella Ma Melillo, Franco Aversa, Chiara Cattaneo, Bruno Martino, Giulia Dragonetti, Annamaria Nosari, Lucia Prezioso, Maria Ilaria Del Principe, Marta Stanzani, Nicola Stefano Fracchiolla, Stelvio Ballanti, Gianpaolo Nadali, Francesco Marchesi, Simone Cesaro, Barbara Veggia, Marco Picardi, Anna Candoni, Alessandro Busca, Marco Gazzola, Livio Pagano, Valentina Mancini, Marianna Criscuolo, Pagano, Livio, Dragonetti, Giulia, Cattaneo, Chiara, Marchesi, Francesco, Veggia, Barbara, Busca, Alessandro, Candoni, Anna, Prezioso, Lucia, Criscuolo, Marianna, Cesaro, Simone, Delia, Mario, Fanci, Rosa, Stanzani, Marta, Ferrari, Antonella, Martino, Bruno, Melillo, Lorella, Nadali, Gianpaolo, Simonetti, Edoardo, Ballanti, Stelvio, Picardi, Marco, Castagnola, Carlo, Decembrino, Nunzia, Gazzola, Marco, Fracchiolla, Nicola Stefano, Mancini, Valentina, Nosari, Annamaria, Principe, Maria Ilaria Del, Aversa, Franco, and Tumbarello, Mario
- Subjects
0301 basic medicine ,Antifungal ,medicine.medical_specialty ,Antifungal Agents ,medicine.drug_class ,medicine.medical_treatment ,030106 microbiology ,Hematopoietic stem cell transplantation ,03 medical and health sciences ,Internal medicine ,hemic and lymphatic diseases ,Candidemia ,Hematologic Neoplasms ,Hematopoietic Stem Cell Transplantation ,Humans ,Incidence ,Retrospective Studies ,Epidemiology ,medicine ,In patient ,Intensive care medicine ,Online Only Articles ,skin and connective tissue diseases ,Candida infection, hematological malignacy, adult, pediatric, mortality ,Candidemia, hematologic malignancies ,Candida infection ,business.industry ,Incidence (epidemiology) ,adult ,Retrospective cohort study ,Hematology ,equipment and supplies ,bacterial infections and mycoses ,Settore MED/15 ,mortality ,Settore MED/15 - MALATTIE DEL SANGUE ,surgical procedures, operative ,pediatric ,Multicenter study ,hematological malignacy ,Conventional chemotherapy ,sense organs ,business - Abstract
The epidemiology of invasive fungal infections (IFI) among patients with hematologic malignancies who are undergoing either conventional chemotherapy or hematopoietic stem cell transplantation (HSCT) is changing due to the introduction of new, effective antifungal agents for both prophylaxis and
- Published
- 2017
36. Correspondence in reference to the previously published manuscript: Reduction of cycles of bendamustine plus rituximab therapy in the cases with good response for indolent B-cell lymphomas.
- Author
-
Autore F, Fresa A, Innocenti I, Principe MID, Maglione R, Stefanizzi C, Pelliccia S, Romeo A, Cimino G, Papa E, Padua L, Andriani A, Mengarelli A, Tafuri A, Ditto C, Mauro FR, Del Poeta G, and Laurenti L
- Subjects
- Humans, Aged, Rituximab, Bendamustine Hydrochloride, Antineoplastic Combined Chemotherapy Protocols adverse effects, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Lymphoma, B-Cell drug therapy, Lymphoma, B-Cell etiology, Lymphoma, Non-Hodgkin drug therapy
- Abstract
Takezaki et al. analyzed the outcome of 57 patients with indolent lymphomas treated with Bendamustine plus Rituximab (BR) according to the number of cycles received, showing that patients who discontinued BR after four cycles had similar outcomes compared to patients who received five or six cycles. Considering the similarities but also the differences between indolent lymphomas and chronic lymphocytic leukemia (CLL), we enriched the results obtained with a cohort of CLL patients treated with BR starting from the experience of the Lazio region group on CLL. Out of 115 patients, 97 (84%) received 4-6 cycles of BR, while 18 (16%) received 1-3 cycles. The outcome of the group of patients who received at least 4 cycles was superior in terms of response rate (ORR 96% vs. ORR 83%, p = 0.041; CR 58% vs. CR 28%, p = 0.052 respectively) and PFS [median PFS 52.6 (40.3-64.9) versus 26.2 (19.3-33.0) months, p < 0.001]. The number of patients undergoing 4 cycles of BR (4-cycles group) and 5-6 cycles (over-4-cycles group) was 9 and 88, respectively. Compared to analysis conducted by the Japanese group in indolent lymphomas, in CLL we did not observe any difference between the outcome of the 4-cycles group and the over-4-cycles group in terms of ORR (89% vs. 97%, p = 0.268) and in survival [median PFS 40.8 (13.7-67.8) versus 52.6 (38.7-66.5) months, p = 0.117]. Moreover, we observed that patients who achieved a clinical CR showed overlapping outcomes with patients who received more than 4 cycles [CR vs. non-CR median PFS not reached vs. 11.0 months; over-4-cycles group median PFS 52.6 months (40.3-64.9); p < 0.001]. Nowadays chemoimmunotherapy with BR is reserved to fit elderly CLL patients, and there are many chemo-free treatment options available; therefore, discontinuation after 4 cycles may be permissible in patients who obtained a CR in order to limit toxicity as much as possible., (© 2022 John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.